Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome
Status:
Completed
Trial end date:
2018-06-04
Target enrollment:
Participant gender:
Summary
This is a Phase 2, single-centre, single-arm, open-label study of the safety, tolerability,
and effects on biomarkers of PBI-4050 in subjects with Alström syndrome for a treatment
duration of 24 weeks.
Subjects who complete the initial 24 weeks of treatment may continue treatment for an
additional 36 or 48 weeks, provided the subject signs informed consent.
Phase:
Phase 2
Details
Lead Sponsor:
Liminal BioSciences Ltd. ProMetic BioSciences Inc.